Whitehawk Therapeutics Set to Showcase Innovations at Oncology Summit

On May 21, 2025, Whitehawk Therapeutics, Inc., a company focused on developing advanced oncology therapeutics, announced that their president and CEO, Dave Lennon, PhD, will take part in a fireside chat at the upcoming TD Cowen 6th Annual Oncology Innovation Summit. This event is scheduled for May 28, 2025, at 2:30 PM ET.

Whitehawk is known for its unique approach in applying advanced technologies to established tumor biology, with an aim to enhance and deliver more effective antibody-drug conjugate (ADC) cancer treatments. Their participation in this summit reflects the company's commitment to pushing the boundaries of cancer treatment protocols and integrating innovative strategies into their therapeutic offerings.

The TD Cowen Summit serves as a critical platform, focusing on oncology innovation and discussing the latest advancements within the field. It's a gathering aimed at stakeholders from various backgrounds, including clinicians, researchers, and investors, all eager to discuss and evaluate the evolving landscape of cancer therapeutics. A key highlight of this year's summit is the potential insights shared by industry leaders, including Dr. Lennon, who will shed light on the challenges and future directions for developing ADCs.

For those unable to attend, Whitehawk Therapeutics will provide a live webcast of the fireside chat. This webcast will also be available for replay for about 30 days, allowing interested parties to catch up on what promises to be an engaging and informative discussion. Interested individuals can find the webcast on the Whitehawk Therapeutics investor relations website.

About Whitehawk Therapeutics

Founded with a mission to redefine cancer treatment, Whitehawk Therapeutics has developed a cutting-edge ADC portfolio engineered specifically to tackle the issues faced by previous generations of cancer therapies. These advanced treatments are expected to deliver meaningful impacts for patients suffering from difficult-to-treat cancers.

The company's ADC assets have been acquired through an exclusive development and global commercialization agreement with WuXi Biologics, ensuring that they leverage the best available scientific resources and technology. This strategic move not only enhances their product offerings but also signifies their commitment to creating impactful solutions for oncological care.

Whitehawk Therapeutics is furthering their mission by actively engaging in discussions and partnerships, like the one occurring at the TD Cowen Summit. They understand the importance of collaboration and knowledge sharing among peers to push for innovations that can significantly change patient outcomes in oncology.

To learn more about Whitehawk Therapeutics and their ongoing projects and innovations, you can visit their official website at www.whitehawktx.com or connect with them on LinkedIn for the latest updates regarding their endeavors.

In conclusion, the TD Cowen 6th Annual Oncology Innovation Summit represents not only an opportunity for Whitehawk Therapeutics to showcase their advancements but also highlights their dedication to leading the charge in oncology therapeutics. This event will likely resonate throughout the healthcare community as new ideas and solutions are discussed and developed. It serves as a reminder of the ongoing battle against cancer and the tireless efforts of those in the field determined to find more effective treatments for patients around the globe.